Hypersence Investor Data Room
A Projected $3 Billion Exit Opportunity in Consumer Brain Health—with Alzheimer’s Upside Beyond It
Hypersence is raising a $3 million seed round to commercialize MemorySPEX™, our patent-pending NeuroWellness™ wearable designed to support cognitive performance—as easily as putting on a pair of glasses.
Based on our internal financial projections, the consumer wellness strategy alone has the potential to support a forecasted $3 billion exit valuation, excluding any potential revenue associated with the treatment of Alzheimer’s disease.
MemorySPEX™ combines neuroscience and wearable technology to compete in the approximately $14 billion U.S. brain-health market. The technology was recognized with the Chairman’s Choice Award at Stanford University’s Global Innovation Challenge and is supported by a growing body of scientific research into 40 Hz sensory stimulation.
Our strategy is to first commercialize MemorySPEX™ as a safe, non-invasive consumer wellness product. Our longer-term objective is to conduct the clinical and regulatory work necessary to pursue an FDA-cleared indication related to Alzheimer’s disease, subject to successful clinical validation and FDA review.
The $3 million seed round will support product development, manufacturing, commercialization, clinical research, and company growth as we work to build a scalable consumer brain-health platform capable of helping millions of people achieve dreams of a better life.
Explore the MemorySPEX™ Investment Opportunity
Review our Investor Video, Pitch Deck, Executive Summary, Financial Model, and supporting due-diligence materials below.
If MemorySPEX™ may be a fit for your investment portfolio, schedule a meeting with Hypersence founder and CEO Kim Lavine to discuss the opportunity.
Why MemorySPEX™—and Why Now?
Why have physicians invested in MemorySPEX™?
How can a simple, non-invasive wearable address the rapidly growing demand for better brain health and cognitive performance?
Why do we believe MemorySPEX™ has the potential to define an entirely new NeuroWellness™ category—and support a multi-billion-dollar exit?
Watch this brief presentation to learn about the technology, market opportunity, commercialization strategy, and long-term Alzheimer’s vision behind MemorySPEX™.
The market is enormous. The need is urgent. And the time to transform brain health is now.
Forecasted $3 billion exit valuation based on our internal financial model and consumer wellness strategy alone
Potential Alzheimer’s treatment opportunity not included in that projected valuation
Approximately $14 billion U.S. brain-health market
Patent-pending wearable technology
Stanford University Chairman’s Choice Award winner
Growing scientific research into 40 Hz sensory stimulation
Safe, non-invasive technology designed for the consumer wellness market
Long-term clinical and regulatory strategy related to Alzheimer’s disease
Experienced leadership with a history of developing and commercializing innovative consumer products
Due Diligence Materials
(email me at kim@hypersence.com for financials in Excel format.)
FDA General Wellness Policy for Low Risk Devices
The information contained herein is not an offer to sell, or a solicitation of an offer to buy, any securities and is qualified in its entirety by the more complete information, including risks of investment, provided by Hypersence, in its sole discretion, to certain qualified investors who meet certain investor criteria. There is no assurance that we will achieve any of our investment objectives, and investment results may vary substantially over time.